Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ChiCTR2600118517) titled 'Omalizumab combined with Specific Immunotherapy in the treatment of Allergic asthma: An Investigator-Initiated Trial(OSIA-IIT)' on Feb. 6.
Study Type: Interventional study
Study Design:
Non randomized control
Primary Sponsor: Fudan University Affiliated Zhongshan Hospital
Condition:
Allergic asthma
Intervention:
Intervention groups (Group A, Group B and Group C):Group A Intervention:
Patients received specific immunotherapy (AIT) using a single-dose rapid protocol for 52 weeks, with an overall observation period of 52 weeks
follow-up after 52 weeks was conducted based on patient condition. If acute asthm...